Rani Therapeutics (NASDAQ:RANI – Get Free Report) and Surrozen (NASDAQ:SRZN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Earnings & Valuation
This table compares Rani Therapeutics and Surrozen”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rani Therapeutics | $1.63 million | 67.22 | -$29.67 million | ($0.27) | -2.91 |
| Surrozen | $3.48 million | 56.54 | -$242.03 million | ($40.55) | -0.42 |
Profitability
This table compares Rani Therapeutics and Surrozen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
| Surrozen | -2,885.33% | N/A | -93.62% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Rani Therapeutics and Surrozen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
Rani Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 1,013.23%. Surrozen has a consensus target price of $45.00, indicating a potential upside of 165.55%. Given Rani Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Rani Therapeutics is more favorable than Surrozen.
Insider & Institutional Ownership
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Summary
Rani Therapeutics beats Surrozen on 8 of the 13 factors compared between the two stocks.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
